Treatment of prostatic carcinoma by gonadotropin inhibition with danazol. A preliminary report

Freedman Dl, D L Freedman, K Carlström, Kjell Carlström, Esposti Pl, P. L. Esposti, P O Hedlund, Hedlund Po
Scandinavian journal of urology and nephrology. Supplementum · 1980 · vol. 55 , pp. 173–5 · PMID:6782665 · W2415069824
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This preliminary report investigated the effect of oral danazol in five prostate cancer patients, observing marked reductions in gonadotropin and testosterone levels with encouraging clinical and cytological results after 16 weeks.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of an oral gonadotropin agent--Danazol--on 5 patients with prostatic carcinoma was investigated. A phase 2 pilot study, using a combination of repeated clinical findings, hormone analyses and cytological examinations, allowed some assessment of results after 16 weeks. There was a marked fall in gonadotropin and testosterone serum levels in all patients. Despite a minor rate of cancer remission, results of clinical and cytological examinations were encouraging enough to stimulate further investigations.

My notes (saved in your browser only)

MeSH descriptors

Danazol Follicle Stimulating Hormone Luteinizing Hormone Pregnadienes Prostatic Neoplasms Danazol Danazol Follicle Stimulating Hormone Humans Luteinizing Hormone Male Pregnadienes Prostatic Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T10:56:25.982381+00:00
pubmed
last seen: 2026-10-08T21:58:26.348914+00:00
License: CC0 · commercial use OK